91 148
[3]
Daffner RH, Lupetin AR, Dash N, Deeb ZL, Sefczek RJ, Schapiro RL. MRI in the detection of malignant infiltration of bone marrow. AJR Am J Roentgenol 1986;146:353–8.
[4]
Lecouvet FE, Geukens D, Stainier A, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effec- tiveness and comparison with current detection strategies. J Clin Oncol 2007;25:3281–7.
[5]
Lecouvet FE, El Mouedden J, Collette L, et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging re- place Tc 99m bone scanning and computed tomography for single- step detection of metastases in patients with high-risk prostate cancer? Eur Urol 2012;62:68–75.
[6]
Woo S, Kim SY, Kim SH, Cho JY. JOURNAL CLUB: identification of bone metastasis with routine prostate MRI: a study of patients with newly diagnosed prostate cancer. AJR Am J Roentgenol 2016;206: 1156–63.
[7]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1–34.[8]
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.
[9]
Piccardo A, Paparo F, Piccazzo R, et al. Value of fused 18F-Choline- PET/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after EBRT: preliminary results. Biomed Res Int 2014;2014:103718.[10]
Suh CH, Park SH. Successful publication of systematic review and meta-analysis of studies evaluating diagnostic test accuracy. Kore- an J Radiol 2016;17:5–6.
[11]
KimKW, Lee J, Choi SH, Huh J, Park SH. Systematic review andmeta- analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers—part I. General guidance and tips. Korean J Radiol 2015;16:1175–87.[12]
Lee J, KimKW, Choi SH, Huh J, Park SH. Systematic review andmeta- analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers—part II. Statistical methods of meta- analysis. Korean J Radiol 2015;16:1188–96.[13]
Deeks JJ, Macaskill P, Irwig L. The performance of tests of publica- tion bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58: 882–93.[14] Higgins J, Green S. Cochrane handbook for systematic reviews of
interventions. Version 5.1.0. The Cochrane Collaboration.
http:// handbook.cochrane.org/chapter_9/9_5_2_identifying_and_ measuring_heterogeneity.htm.
[15]
Conde-Moreno AJ, Herrando-Parreno G, Muelas-Soria R, et al. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-comput- ed tomography (choline-PET/CT) for selecting treatments in recur- rent prostate cancer. Clin Transl Oncol 2017;19:553–61.[16]
Kitajima K, Murphy RC, Nathan MA, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C- choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med 2014;55:223–32.
[17]
Mosavi F, Johansson S, Sandberg DT, Turesson I, Sorensen J, Ahl- strom H. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol 2012;199: 1114–20.[18]
Pasoglou V, Michoux N, Peeters F, et al. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. Radiology 2015; 275:155–66.
[19]
Vargas HA, Schor-Bardach R, Long N, et al. Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical fea- tures associated with their diagnosis. Abdom Radiol (NY) 2017;42: 271–7.[20]
Venkitaraman R, Cook GJ, Dearnaley DP, et al. Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer? Clin Oncol 2009;21:39–42.[21]
Cheng X, Li Y, Xu Z, Bao L, Li D, Wang J. Comparison of 18F-FDG PET/ CT with bone scintigraphy for detection of bone metastasis: a meta- analysis. Acta Radiol 2011;52:779–87.[22]
Lecouvet FE. Whole-body MR imaging: musculoskeletal applica- tions. Radiology 2016;279:345–65.[23]
Padhani AR, Lecouvet FE, Tunariu N, et al. METastasis Reporting and Data System for Prostate Cancer: practical guidelines for acquisi- tion, interpretation, and reporting of whole-body magnetic reso- nance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 2017;71:81–92.[24]
Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg 1940;112:138–49.[25]
Messiou C, Collins DJ, Giles S, de Bono JS, Bianchini D, de Souza NM. Assessing response in bone metastases in prostate cancer with diffusion weighted MRI. Eur Radiol 2011;21:2169–77.
[26]
Dafni H, Kim SJ, Bankson JA, Sankaranarayanapillai M, Ronen SM. Macromolecular dynamic contrast-enhanced (DCE) MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation. Magn Reson Med 2008;60: 822–33.E U R O P E A N U R O L O G Y 7 3 ( 2 0 1 8 ) 8 1 – 9 1
91